Naloxone
Naloxone is a semi-synthetic opioid antagonist of the morphinan class. It is derived from oxymorphone by a single structural change that abolishes agonist activity entirely. It blocks opioid receptors in the brain without activating them, physically displacing opioids from their binding sites and reversing overdose-induced respiratory failure.[1][2]
Naloxone is a semi-synthetic opioid antagonist of the morphinan class. It is the N-allyl derivative of oxymorphone — a single structural change that abolishes agonist activity. Naloxone is a competitive antagonist at μ-opioid receptors, stalling the receptor in a distinct inactive conformation[1] and displacing opioid agonists from their binding sites.[2]
Synthesized in 1960 by Jack Fishman, naloxone was the first opioid antagonist entirely free of partial agonist effects.[3] FDA-approved as an injectable in 1971, it became the standard treatment for opioid overdose and a WHO Essential Medicine.[4] Since 2023, naloxone nasal spray has been available over the counter in the United States without a prescription.[5]
Subjective effects include no perceptible change in opioid-naive individuals — any increase in pain sensitivity falls below conscious awareness. In opioid-dependent individuals, the experience is defined by abrupt reversal: consciousness returns within minutes, but with distress more intense than ordinary withdrawal because receptor occupancy shifts instantaneously.[6] Anxiety, agitation, nausea, vomiting, sweating, and intense opioid craving are characteristic.
Naloxone produces no dependence and carries negligible direct toxicity.[2] The risks come from reversal itself: abrupt opioid removal can cause cardiovascular stress and, rarely, fluid in the lungs,[7] and the short duration means overdose may return if the opioid outlasts it.[8][9] Six decades of clinical use make it one of the best-characterized emergency medications in existence.
History[edit]
Discovery
In 1960, chemist Jack Fishman synthesized naloxone by making a single change to oxymorphone — replacing the N-methyl group with an N-allyl substituent — yielding the first opioid antagonist with no agonist activity whatsoever.[3] Animal testing showed it was 10–20 times more potent as an antagonist than its predecessor nalorphine, and the compound was patented in 1961.[3] The FDA approved it in 1971 under the brand name Narcan, establishing it as the standard emergency treatment for opioid overdose.[10]
Public health expansion
Beginning in the early 2000s, take-home naloxone programs brought emergency kits directly to the people most likely to witness overdoses — peers, family members, and first responders.[4] Scotland's national program, launched in 2011, cut opioid-related deaths by 36% in the four weeks after prison release during its first three years.[11] In 2023, the FDA approved naloxone nasal spray for over-the-counter sale, completing a decades-long shift from hospital-only to pocket-carried.[5]
The name "naloxone" is built from its chemistry: n-al (N-allyl) + ox (oxymorphone) + -one (the C-6 ketone). The brand name Narcan — short for "narcotic counteractant" — became so synonymous with overdose reversal that it now functions as a genericized trademark in public health messaging. In harm reduction communities, "carrying Narcan" has become shorthand for overdose preparedness, a visible symbol of the peer-based public health movement that reshaped opioid crisis response.
Chemistry[edit]
Structural class
Naloxone belongs to the morphinan chemical class — the same family as morphine and oxymorphone. It is the N-allyl derivative of oxymorphone: replacing a single substituent on the nitrogen abolishes agonist activity entirely, producing a pure competitive antagonist.[3] Its molecular formula is C₁₉H₂₁NO₄ (molecular weight 327.4 g/mol).
Stereochemistry
Naloxone has four stereocenters, but only one mirror-image form is active at opioid receptors.citation needed All pharmaceutical preparations contain this single active stereoisomer. The hydrochloride salt is the standard pharmaceutical form, chosen for its high water solubility (73 mg/mL) — a property that makes concentrated nasal spray formulations possible.
Pharmacology[edit]
Mechanism of action
Naloxone binds opioid receptors — primarily the μ-opioid — and physically displaces opioid molecules from their binding sites without activating them.[2] A 2025 structural study showed it locks the receptor in a distinct inactive state, explaining why it produces no opioid effect of its own.[1] The degree of reversal depends on relative concentrations of agonist and antagonist — high-potency synthetics like fentanyl require higher or repeated doses.[2]
Pharmacokinetics
Naloxone is cleared rapidly by the liver with a half-life of 60–120 minutes.[12][13] It is broken down by glucuronidation rather than the liver's main drug-processing enzymes, so it has minimal interactions with other medications — a useful property for a rescue drug administered in complex polypharmacy situations.[14] Bioavailability varies by route, from near-zero for dilute intranasal formulations to complete for intravenous injection.[2][12]
Oral naloxone is not used for overdose reversal — first-pass liver metabolism destroys nearly all of it.[4] In Suboxone (buprenorphine/naloxone), this property serves as an abuse deterrent: naloxone has no effect when the tablet dissolves under the tongue, but triggers withdrawal if the mixture is injected.[4]
Neuroscience[edit]
Where it acts
Naloxone's most critical target is the brainstem, where opioids suppress the neurons that control breathing — displacing them restores respiratory drive and is the mechanism of overdose reversal.[13] In the brain's reward circuit, blocking opioid receptors abolishes euphoria and, in dependent individuals, triggers intense dysphoria and craving.[6] It also reverses the descending pain suppression opioids provide, which can unmask pain in patients receiving opioid analgesia.
Why it matters
Naloxone also functions as a research tool. By blocking the brain's own opioid receptors simultaneously, it reveals how much the body's natural opioid system contributes to everyday mood, pain tolerance, and social bonding.citation needed
Chronic opioid use builds opposing adaptations that are masked as long as opioids are present. Naloxone strips that mask away all at once, which is why precipitated withdrawal is more severe than spontaneous detoxification — the full force of the body's anti-reward response arrives in minutes rather than days.[6]
The most pressing unresolved questions involve high-affinity synthetic opioids — carfentanil and nitazenes — whose binding resists displacement at standard naloxone doses.[2] Combined xylazine-opioid overdoses present a separate problem: naloxone reverses only the opioid component, while xylazine's sedative effects persist.[15] Long-acting depot naloxone formulations are being explored to provide sustained coverage against slow-clearing synthetics.[16]
Subjective Effects[edit]
Naloxone is not psychoactive in the ordinary sense. In opioid-naive individuals, clinical doses produce no perceptible experience. In opioid-dependent individuals, the experience is defined entirely by abrupt reversal — consciousness returns within minutes, accompanied by acute physical and emotional distress proportional to the degree of dependence.[6]
Naloxone is best understood alongside naltrexone, which shares its pure antagonist pharmacology but lasts far longer. Where naltrexone provides sustained blockade for maintenance therapy, naloxone's short window makes it a rescue tool — pharmacologically decisive in emergencies, but not suited for ongoing use.
Synthesized in 1960 by Jack Fishman at Endo Laboratories, naloxone was the first opioid antagonist entirely free of the partial agonist effects that limited predecessors such as nalorphine.[3] FDA-approved as an injectable in 1971, it became the cornerstone of emergency overdose reversal and a WHO Essential Medicine.[4] Since 2023, naloxone nasal spray has been available over the counter in the United States.[5]
Subjective effects are absent in opioid-naive individuals; in opioid-dependent individuals, naloxone precipitates acute withdrawal including anxiety, agitation, nausea, vomiting, and intense dysphoria. The experience is defined by abrupt pharmacological reversal — consciousness returns rapidly, accompanied by somatic distress that exceeds spontaneous withdrawal because receptor occupancy changes instantaneously.[6] Craving and immediate opioid-seeking behavior are characteristic unsought consequences.
Naloxone produces no dependence of any kind and carries negligible direct toxicity.[2] The primary risk is precipitated withdrawal in opioid-dependent individuals, which can trigger cardiovascular stress and, rarely, pulmonary edema;[7] its short half-life creates a renarcotization hazard, compounded by high-affinity synthetic opioids that resist displacement at standard doses.[8][9] Six decades of clinical use make naloxone one of the best-characterized emergency medications in existence.
History[edit]
Discovery
In 1960, chemist Jack Fishman, working in Mozes J. Lewenstein's laboratory at Endo Laboratories, synthesized naloxone by replacing the N-methyl group of oxymorphone with an N-allyl substituent — a modification proposed by Harold Blumberg that yielded the first opioid antagonist entirely free of agonist activity.[3] Animal testing showed naloxone was 10–20 times more potent as an antagonist than nalorphine, and the compound was patented in 1961.[3]
Clinical adoption
The FDA approved naloxone injection in 1971 under the brand name Narcan, establishing it as the standard treatment for opioid overdose reversal.[10] Over the following decades it earned a place on the WHO Model List of Essential Medicines and became one of the most widely deployed emergency pharmacological agents globally.[4]
Public health expansion
Beginning in the early 2000s, take-home naloxone programs placed emergency kits directly in the hands of people likely to witness overdoses — peers, family members, and first responders.[4] Scotland's National Naloxone Programme, launched in 2011, demonstrated a 36% reduction in opioid-related deaths within four weeks of prison release over its first three years.[11] The arc reached its current peak in 2023, when the FDA approved naloxone nasal spray for over-the-counter sale without prescription.[5]
The name "naloxone" derives from its chemical relationship to its parent compounds: n-al (N-allyl) + ox (oxymorphone) + -one (the C-6 ketone). The brand name Narcan — a contraction of "narcotic counteractant" — became so synonymous with overdose reversal that it functions as a genericized trademark in public health messaging. In harm reduction communities, "carrying Narcan" has become shorthand for overdose preparedness, a visible symbol of the peer-based public health movement that reshaped opioid crisis response.
Chemistry[edit]
Structural class
Naloxone belongs to the morphinan chemical class — specifically the 4,5-epoxy-morphinan subclass shared by morphine, oxymorphone, and naltrexone. It is the N-allyl derivative of oxymorphone: the N-methyl group on oxymorphone's nitrogen is replaced by an N-allyl (prop-2-en-1-yl) group. This single substitution abolishes agonist activity while preserving high-affinity receptor binding, producing a pure competitive antagonist.[3]
The morphinan core consists of a pentacyclic ring system: three fused six-membered rings derived from phenanthrene, a piperidine ring containing nitrogen, and a tetrahydrofuran ring formed by the 4,5-epoxy bridge. The C-3 phenolic hydroxyl, C-14 tertiary hydroxyl, C-6 ketone, and the N-allyl substituent are the defining functional groups.
Molecular properties
| Molecular formula | C₁₉H₂₁NO₄ |
| Molecular weight | 327.4 g/mol |
Stereochemistry
Naloxone has four stereocenters (4R, 4aS, 7aR, 12bS in systematic numbering). Only the (−)-enantiomer — the naturally occurring morphinan configuration — is active at opioid receptors.citation needed All pharmaceutical preparations contain the single active stereoisomer.
Physical properties
The hydrochloride salt is the standard pharmaceutical form, chosen for its high aqueous solubility (73 mg/mL), which enables the concentrated nasal spray formulations critical for intranasal delivery. The free base is poorly water-soluble. Naloxone is stable under standard storage conditions but susceptible to oxidative degradation; formulations are typically stored protected from light.
Pharmacology[edit]
Mechanism of action
Naloxone is a competitive antagonist at opioid receptors, binding with highest affinity to the μ-opioid (MOR) and lower affinity to kappa (κ-opioid) and delta (δ-opioid) subtypes.[2] It reverses opioid effects by physically displacing agonist molecules from receptor binding sites; the degree of displacement depends on relative affinities and concentrations of agonist and antagonist.[2]
A 2025 cryo-EM study revealed that naloxone stalls the mu-opioid receptor in a "latent" conformational state — distinct from both the fully inactive and agonist-activated conformations — providing a structural explanation for its pure antagonist properties.[1] At very high concentrations, naloxone can dampen baseline receptor signaling (inverse agonism), but competitive antagonism dominates at all clinically relevant doses.[1]
Naloxone has no meaningful affinity for the nociceptin receptor (NOP/ORL1).
Pharmacokinetics
Bioavailability is route-dependent, ranging from near-zero for dilute intranasal formulations to complete for intravenous injection.[2][12] The compound distributes extensively into tissues and is cleared rapidly by the liver, with an half-life of 60–120 minutes in most studies.[12][13]
Naloxone is broken down primarily by glucuronidation (UGT enzymes), not the cytochrome P450 system.[14] Its main metabolite, naloxone-3-glucuronide, is pharmacologically inactive.[2] This metabolic pathway carries a clinically useful implication: naloxone has minimal risk of drug-drug interactions through liver enzymes — a favorable property for a rescue medication administered in emergency and polypharmacy settings.
Oral bioavailability is very low due to extensive first-pass metabolism. Oral naloxone is not used for overdose reversal; oral formulations serve as abuse-deterrent components in combination products like buprenorphine/naloxone (Suboxone).[4]
Neuroscience[edit]
Where it acts
Naloxone's neural effects are defined by blockade of opioid signaling across three critical brain circuits. In the ventral tegmental area (ventral tegmental area), opioid agonists disinhibit dopamine neurons that drive reward; naloxone blocks this cascade, abolishing opioid-mediated euphoria and, in dependent individuals, precipitating dysphoria and craving.[6] In the periaqueductal gray and rostral ventromedial medulla, it reverses the descending pain suppression that opioids provide, which is why it can unmask pain in patients receiving opioid analgesia.
The most clinically consequential target is the pre-Bötzinger complex and associated brainstem respiratory nuclei — the site where opioid agonists suppress breathing. Naloxone restores respiratory drive by displacing agonists from these neurons.[13]
Why it matters
Naloxone also serves as a pharmacological probe for the brain's own opioid system. By blocking mu, kappa, and delta receptors simultaneously, it reveals the tonic contribution of endogenous opioid peptides — endorphins, enkephalins, dynorphins — to baseline mood, pain processing, and reward. Naloxone challenge paradigms have demonstrated that endogenous opioids contribute to placebo analgesia, social bonding, and exercise-induced mood elevation.citation needed
The opponent process framework helps explain why precipitated withdrawal is so severe: chronic opioid exposure builds anti-reward neuroadaptations masked by ongoing agonist activity. Naloxone unmasks these opponent processes at full intensity, producing withdrawal more acute than the gradual decline of spontaneous detoxification.[6]
Key unresolved questions include optimal naloxone dosing for high-affinity synthetic opioids (carfentanil, nitazenes) whose receptor kinetics resist standard displacement,[2] management of combined xylazine-opioid overdoses where naloxone reverses only the opioid component,[15] and whether long-acting depot naloxone formulations can provide sustained antagonist coverage against slow-clearing synthetics.[16]
Subjective Effects[edit]
Naloxone is not psychoactive in the conventional sense. In opioid-naive individuals, clinical doses produce no perceptible subjective change — endogenous opioid blockade may yield subtle increases in pain sensitivity, but these fall below the threshold of conscious experience. The entire experiential profile is contingent on the recipient's opioid status: in opioid-dependent individuals, naloxone triggers an abrupt withdrawal whose intensity is proportional to the degree of physical dependence and whose onset — within minutes of injection — is faster and more severe than spontaneous withdrawal.[6]
Naloxone is best understood alongside naltrexone, which shares its pure antagonist pharmacology but differs in duration (hours versus days) and oral viability. Where naltrexone provides sustained blockade for maintenance therapy, naloxone's short action window makes it a rescue tool — pharmacologically decisive but temporally limited.
Effect Grid
The common dose range (0.4–2 mg IV/IM, 1–4 mg IN) represents the standard overdose reversal window. In opioid-naive individuals, these doses produce no subjective effects. In opioid-dependent individuals receiving agonists, competitive displacement restores respiratory drive within minutes.
Precipitated withdrawal at common doses produces moderate anxiety, dysphoria, nausea, restlessness, excessive sweating, yawning, watery eyes, and craving. Pain enhancement occurs as opioid analgesia is reversed. Tachycardia and mild hypertension reflect sympathetic activation.
Duration of antagonist effect is 30–120 minutes depending on route. Renarcotization is possible if the opioid being reversed has a longer half-life than naloxone, necessitating monitoring or repeat dosing.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Pupil dilation · Restlessness · Watery eyes · Respiratory stimulation · Spontaneous body sensations · Vomiting · Wakefulness · Dehydration sensation · Breathing alteration · Muscle tension · Pain enhancement · Trembling · Yawning · Dizziness · Heart rate perception changes · Insomnia · Involuntary body movements · Physical fatigue · Appetite suppression · Headache
Spontaneous body sensations · Vomiting · Wakefulness · Dehydration sensation · Breathing alteration · Muscle tension · Pain enhancement · Trembling · Yawning · Dizziness · Heart rate perception changes · Insomnia · Involuntary body movements · Physical fatigue · Appetite suppression · Headache
Anhedonia · Emotional lability · Empathy suppression
Timeline
Nasal mucosal absorption begins. Clinical onset may lag behind IM due to absorption kinetics. First signs of opioid reversal or withdrawal onset in dependent individuals.
Peak plasma reached (Tmax 15–30 min). Full opioid antagonism established. Precipitated withdrawal at maximum intensity in opioid-dependent individuals.
Declining plasma levels and receptor occupancy. Renarcotization risk present, especially with long-acting opioids.
⚠ Avoid driving or operating machinery until fully assessed by medical personnel.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- None
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- —
Toxicity
Naloxone has very low direct toxicity. It does not cause respiratory depression, sedation, or organ damage at any clinically relevant dose in opioid-naive individuals, and no human fatalities have been attributed to naloxone itself.[2]
Database classification of naloxone as high-toxicity is incorrect. This rating was inherited from the opioid pharmacological class, but naloxone is an opioid antagonist — it reverses toxicity rather than causing it.
Precipitated withdrawal
The principal adverse effect is precipitated withdrawal — an abrupt, severe withdrawal that occurs when naloxone displaces opioids from receptors in opioid-dependent individuals.[6] Symptoms include anxiety, agitation, nausea, vomiting, diarrhea, sweating, muscle pain, rapid heart rate, and high blood pressure. Onset is within 2–5 minutes of injection and 15–30 minutes with nasal formulations.[2]
Heart and circulation
Abrupt opioid reversal triggers an epinephrine surge. This can cause high blood pressure, rapid heart rate, and abnormal heart rhythms, and is more pronounced at higher doses and in those with pre-existing heart conditions.[15]
Pulmonary edema
Fluid can accumulate in the lungs (noncardiogenic pulmonary edema) — a rare but documented consequence of abrupt opioid reversal, caused by adrenaline-mediated fluid shifts.[7] The condition is more common at higher doses and is generally manageable with medical treatment.
Psychological risks
Naloxone does not produce hallucinations, psychosis, or perceptual disturbance. The primary psychological risk is the acute distress of precipitated withdrawal — intense dysphoria, anxiety, and craving that can drive immediate opioid-seeking behavior.
Individuals who leave medical care to seek opioids face elevated overdose risk because tolerance may have been partially reset during antagonist blockade.citation needed The goal of overdose reversal is restored breathing, not full consciousness — a principle that guides dose titration.[2]
Tolerance and dependence
Naloxone does not produce tolerance or dependence of any kind.[2] As a competitive antagonist, it does not trigger the receptor changes that drive opioid tolerance. There is no withdrawal syndrome from stopping it and no abuse potential.
In Suboxone (buprenorphine/naloxone), naloxone is poorly absorbed under the tongue but triggers withdrawal if injected — by design, to discourage misuse.[4]
Drug Interactions
Naloxone's defining interaction is competitive displacement of opioid agonists from their receptors.[2] Standard doses (0.4–0.8 mg IV/IM) reverse heroin and morphine reliably. Fentanyl and its analogs may require higher or repeated doses.[9][15] Carfentanil and nitazenes resist displacement at conventional doses.[13][8]
Naloxone does not reverse xylazine — a sedative increasingly found as a fentanyl adulterant.[15] Only the opioid component of respiratory depression is reversed; xylazine's sedative and circulatory effects persist. Because naloxone is metabolized by glucuronidation rather than liver CYP enzymes, significant drug-drug interactions through metabolism are not expected.[14]
Contraindications
3 knownAbsolute
- Hypersensitivity to naloxone or any formulation component.
Relative
- Known or suspected opioid dependence: Naloxone will precipitate withdrawal. In life-threatening overdose, respiratory failure outweighs withdrawal risk, but cautious dose titration and monitoring are required.[2]
- Heart conditions: The adrenaline surge from abrupt opioid reversal can worsen high blood pressure, abnormal rhythms, and reduced blood flow to the heart.[15]
- Medications sensitive to adrenaline surges: Patients on drugs whose safety depends on stable blood pressure and heart rate require close monitoring after naloxone.citation needed
Harm Reduction[edit]
Forms & Identification
Naloxone comes in two main forms for emergency use: nasal sprays (Narcan 4 mg, RiVive 3 mg), designed for single-use by untrained bystanders, and injectable formulations used in clinical and first-responder settings. Expired naloxone retains some efficacy — a degraded dose is preferable to none.
Guidelines
- Obtain naloxone before it is needed — nasal spray formulations are available over the counter in the United States and through pharmacies or harm reduction programs in many countries.
- Learn the signs of opioid overdose: slow or stopped breathing, blue lips or fingertips, unresponsiveness, gurgling or snoring sounds.
- Administer naloxone at the first sign of overdose — do not wait for certainty. The medication causes no harm to someone who is not experiencing opioid overdose.
- Titrate to breathing, not consciousness — the goal is restored respiratory drive, not full wakefulness. Overly aggressive dosing increases the severity of precipitated withdrawal.
- After administration, stay with the person. Naloxone wears off in 30–90 minutes, and the opioid may outlast it. A second dose may be needed if breathing slows again.
- Always call emergency services, even if the person appears to recover. Renarcotization — the return of overdose symptoms after naloxone wears off — is a documented risk with longer-acting opioids.
Set & Setting
Naloxone is an emergency medication, not a substance of use. The relevant preparation is ensuring it is physically accessible before it is needed: stored where anyone present can find it, carried by people who may witness an opioid overdose, and accompanied by basic training in overdose recognition. Many community health programs and pharmacies provide free naloxone with brief training.
Aftercare & integration. After a naloxone-reversed overdose, the immediate priority is medical observation — renarcotization can occur as naloxone wears off. Hospital observation is recommended for at least 2–4 hours depending on the opioid involved.
Precipitated withdrawal, if it occurs, is intensely uncomfortable but time-limited. Supportive care — hydration, warmth, a calm environment, reassurance — helps manage the acute distress. The craving that follows is a predictable pharmacological response, not a personal failure, and the hours after reversal carry elevated risk of re-use.
For individuals who have experienced overdose, the event is a point of contact with treatment services. Many emergency departments offer direct referral to medication-assisted treatment (buprenorphine, methadone, naltrexone) and peer support at the time of reversal.
Recovery & Support
Naloxone reversal is not treatment for opioid use disorder — it preserves life long enough for treatment to begin. Evidence-based treatments include buprenorphine (Suboxone), methadone, and extended-release naltrexone (Vivitrol), all of which reduce overdose mortality and support sustained recovery.
Peer support organizations, including those that distribute naloxone, often provide the first non-clinical point of contact for people navigating recovery. SAMHSA's National Helpline (1-800-662-4357, US) offers free, confidential referrals to local treatment and support services 24 hours a day.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Slow, shallow, or stopped breathing. Blue or gray lips, fingertips, or skin. Unresponsiveness to voice or sternal rub. Gurgling, choking, or snoring-like sounds. Pinpoint pupils (though not always present with synthetic opioids).
Immediate steps:
- 1. Call emergency services immediately.
- 2. Administer naloxone — one spray in one nostril (nasal) or one injection (IM/IV/SC).
- 3. Place the person in the recovery position (on their side) to prevent choking.
- 4. If breathing does not improve within 2–3 minutes, administer a second dose.
- 5. Continue rescue breathing if trained and the person is not breathing adequately.
- 6. Do NOT leave the person alone. Do NOT place them in water. Do NOT try to induce vomiting.
What to tell the dispatcher: The person is unresponsive and not breathing normally. State what substance was involved, the amount if known, and that naloxone has been administered. Good Samaritan laws in many jurisdictions protect people who call for help during an overdose — fear of legal consequences should not delay the call.
Renarcotization: Naloxone wears off in 30–90 minutes. If the opioid involved is longer-acting (methadone, extended-release formulations, or high doses of fentanyl), overdose symptoms may return. Continue monitoring until emergency medical services arrive.
Legal Status[edit]
Naloxone is not a controlled substance in any major jurisdiction. The global trend since the early 2000s has been toward expanding access — from prescription-only to fully over-the-counter.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not a controlled substance; OTC (nasal spray) | Narcan 4 mg and RiVive 3 mg nasal sprays approved OTC without prescription (March and July 2023).[5] Injectable formulations require prescription in some states; many states have standing orders or pharmacist dispensing authority. Some states mandate co-prescription with opioid prescriptions.[17] |
| United Kingdom | Prescription Only Medicine (POM) | Any member of the public may administer naloxone as a life-saving measure since 2005. Since 2015, drug service staff may supply naloxone without individual prescription. Take-home naloxone programs operate nationally.[4][18] |
| Canada | Not a controlled substance | Available without prescription through pharmacies in several provinces. Provincial programs provide free naloxone kits in many community settings.[5] |
| Australia | Not a controlled substance | Available without prescription in pharmacies. Government-subsidized through harm reduction programs.[5] |
| Italy | OTC | Over-the-counter classification since 1996 — the earliest unrestricted access regime in Europe.[18] |
| France | Some formulations without prescription | Limited non-prescription availability for certain naloxone formulations.[18] |
| EU (general) | Mostly prescription required | Most EU member states require medical prescription. The European Union Drugs Agency (EUDA) recommends expanding access across member states.[18] |
Legal status varies by jurisdiction and changes frequently. This information is not legal advice.
Safety[edit]
- Acute toxicity
- Negligible
- Chronic toxicity
- Negligible
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- None
- Psychological
- None
- Compulsive redosing
- Negligible
- Dose escalation
- Negligible
- Cross-tol.
- —
Toxicity
Naloxone has very low direct toxicity. It does not cause respiratory depression, sedation, or organ damage at any clinically relevant dose in opioid-naive individuals. No human fatalities have been attributed to naloxone itself.[2]
Database classification of naloxone as high-toxicity is incorrect. This rating was inherited from the opioid pharmacological class, but naloxone is an opioid antagonist — it reverses toxicity rather than causing it.
Precipitated withdrawal
The principal adverse effect is precipitated withdrawal in opioid-dependent individuals — an abrupt, severe withdrawal triggered by competitive displacement of agonists from opioid receptors.[6] Symptoms include anxiety, agitation, nausea, vomiting, diarrhea, sweating, muscle pain, rapid heart rate, and high blood pressure. Onset occurs within 2–5 minutes of injection and may be delayed 15–30 minutes with nasal formulations.[2]
Heart and circulation
High blood pressure, rapid heart rate, and abnormal heart rhythms have been documented following naloxone administration, attributed to the epinephrine surge associated with abrupt opioid reversal. These effects are more pronounced at higher doses and in individuals with pre-existing heart conditions.[15]
Pulmonary edema
Fluid accumulation in the lungs (noncardiogenic pulmonary edema) is a rare but documented adverse event, likely caused by adrenaline-mediated fluid shifts following abrupt opioid reversal.[7] The condition is more common at higher doses and is generally manageable with medical treatment.
Psychological risks
Naloxone does not produce hallucinations, psychosis, or perceptual disturbance. The primary psychological risk is the acute distress of precipitated withdrawal — intense dysphoria, anxiety, and craving that can drive immediate opioid-seeking behavior.
This behavioral response carries secondary risk: individuals who leave medical care after naloxone to seek opioids face elevated overdose risk because their tolerance may have been partially reset during the period of antagonist blockade.citation needed The clinical goal of overdose reversal is restoration of adequate breathing, not precipitation of full consciousness or withdrawal — a principle that guides dose titration.[2]
Tolerance and dependence
Naloxone does not produce tolerance. As a competitive antagonist, it does not trigger the receptor changes that drive opioid agonist tolerance. No published literature documents dose-escalation requirements.[2]
Naloxone is not habit-forming and produces no physical or psychological dependence. There is no withdrawal syndrome from stopping naloxone. The compound has no reinforcing properties and no abuse potential.
In buprenorphine/naloxone combinations (Suboxone), naloxone serves as an abuse deterrent: poorly absorbed when taken under the tongue (the intended route) but active if injected, where it precipitates withdrawal and discourages misuse.[4]
Drug Interactions
Naloxone's primary interaction is its defining action: competitive displacement of opioid agonists from opioid receptors. This is the therapeutic basis for overdose reversal.[2]
Interaction severity varies by opioid. Heroin and morphine are reversed at standard doses (0.4–0.8 mg IV/IM). Fentanyl and its analogs may require higher or repeated doses due to greater receptor affinity.[9][15] Carfentanil and nitazenes represent the extreme end, with receptor binding that resists displacement at conventional naloxone doses.[13][8]
Naloxone does not reverse non-opioid depressants. Xylazine, an α2-adrenergic agonist increasingly found as a fentanyl adulterant, is unaffected — only the opioid component of respiratory depression is reversed, while xylazine's sedative and circulatory effects persist.[15]
Because naloxone is metabolized by glucuronidation rather than liver CYP enzymes, significant drug-drug interactions through liver metabolism are not expected.[14]
Contraindications
3 knownAbsolute
- Hypersensitivity to naloxone or any formulation component.
Relative
- Known or suspected opioid dependence: Naloxone will precipitate withdrawal. In life-threatening overdose, respiratory failure outweighs withdrawal risk, but cautious dose titration and monitoring are required.[2]
- Heart conditions: The adrenaline surge from abrupt opioid reversal can worsen high blood pressure, abnormal rhythms, and reduced blood flow to the heart.[15]
- Medications sensitive to adrenaline surges: Patients on drugs whose safety depends on stable blood pressure and heart rate (e.g., MAOIs, certain blood pressure medications) require close monitoring after naloxone.citation needed
Harm Reduction[edit]
Forms & Identification
The structured data module above shows available naloxone formulations and testing information. The most important practical consideration is recognizing which formulation you have and understanding its delivery characteristics: nasal sprays (Narcan 4 mg, RiVive 3 mg) are designed for single-use administration by untrained bystanders, while injectable formulations are used in clinical and first-responder settings. Expired naloxone retains some efficacy and should be used if no unexpired supply is available — a partially degraded dose is preferable to none.
Guidelines
- Obtain naloxone before you need it — nasal spray formulations are available over the counter in the United States and through pharmacies or harm reduction programs in many countries.
- Learn the signs of opioid overdose: slow or stopped breathing, blue lips or fingertips, unresponsiveness, gurgling or snoring sounds.
- Administer naloxone at the first sign of overdose — do not wait for certainty. The medication causes no harm to someone who is not experiencing opioid overdose.
- Titrate to breathing, not consciousness — the goal is restored respiratory drive, not full wakefulness. Overly aggressive dosing increases the severity of precipitated withdrawal.
- After administration, stay with the person. Naloxone wears off in 30–90 minutes, and the opioid may outlast it. A second dose may be needed if breathing slows again.
- Always call emergency services, even if the person appears to recover. Renarcotization — the return of overdose symptoms after naloxone wears off — is a documented risk with longer-acting opioids.
Set & Setting
Naloxone is an emergency medication, not a substance of use — set and setting considerations apply to the overdose response environment rather than to the user. The most effective preparation is ensuring naloxone is physically accessible before it is needed: stored in a known location, carried by anyone who may witness an opioid overdose, and accompanied by basic training in overdose recognition and administration technique. Many community health programs and pharmacies provide free naloxone with brief training sessions.
Aftercare & integration. Following naloxone-reversed overdose, the immediate priority is medical observation — renarcotization can occur as naloxone's effects wear off, and the period immediately after reversal carries elevated risk. Hospital observation is recommended for a minimum of 2–4 hours depending on the opioid involved.
Precipitated withdrawal, if it occurs, is intensely uncomfortable but time-limited. Supportive care — hydration, warmth, a calm environment, reassurance — helps manage the acute distress. The craving that accompanies withdrawal is a predictable pharmacological response, not a personal failure, and the hours following reversal represent a period of heightened vulnerability to re-use.
For individuals who have experienced overdose, the event can serve as a point of contact with treatment services. Many emergency departments offer direct referral to medication-assisted treatment (buprenorphine, methadone, naltrexone) and peer support at the time of reversal.
Recovery & Support
Naloxone reversal is not a treatment for opioid use disorder — it is a bridge that preserves life long enough for treatment to begin. Evidence-based pharmacological treatments include buprenorphine (Suboxone), methadone, and extended-release naltrexone (Vivitrol), all of which reduce overdose mortality and support sustained recovery.
Peer support organizations, including those that distribute naloxone, often provide the first non-clinical point of contact for individuals navigating recovery. National helplines (such as SAMHSA's National Helpline at 1-800-662-4357 in the US) offer free, confidential referrals to local treatment and support services 24 hours a day.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Slow, shallow, or stopped breathing. Blue or gray lips, fingertips, or skin. Unresponsiveness to voice or sternal rub. Gurgling, choking, or snoring-like sounds. Pinpoint pupils (though not always present with synthetic opioids).
Immediate steps:
- 1. Call emergency services immediately.
- 2. Administer naloxone — one spray in one nostril (nasal) or one injection (IM/IV/SC).
- 3. Place the person in the recovery position (on their side) to prevent choking.
- 4. If breathing does not improve within 2–3 minutes, administer a second dose.
- 5. Continue rescue breathing if trained and the person is not breathing adequately.
- 6. Do NOT leave the person alone. Do NOT place them in water. Do NOT try to induce vomiting.
What to tell the dispatcher: The person is unresponsive and not breathing normally. State what substance you believe was involved, the amount if known, and that naloxone has been administered. Good Samaritan laws in many jurisdictions protect people who call for help during an overdose — do not let fear of legal consequences delay the call.
Renarcotization: Naloxone wears off in 30–90 minutes. If the opioid involved is longer-acting (methadone, extended-release formulations, or high doses of fentanyl), overdose symptoms may return. Continue monitoring until emergency medical services arrive.
Legal Status[edit]
Naloxone is not a controlled substance in any major jurisdiction. It has no abuse potential and is not scheduled under international drug control treaties. The global regulatory trend since the early 2000s has been toward expanding access — from prescription-only to pharmacist-dispensed to fully over-the-counter — driven by the escalating opioid overdose crisis.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not a controlled substance; OTC (nasal spray) | Narcan 4 mg and RiVive 3 mg nasal sprays approved OTC without prescription (March and July 2023).[5] Injectable formulations require prescription in some states; many states have standing orders or pharmacist dispensing authority. Some states mandate co-prescription with opioid prescriptions.[17] |
| United Kingdom | Prescription Only Medicine (POM) | Any member of the public may administer naloxone as a life-saving measure since 2005. Since 2015, drug service staff may supply naloxone without individual prescription. Take-home naloxone programs operate nationally.[4][18] |
| Canada | Not a controlled substance | Available without prescription through pharmacies in several provinces. Provincial programs provide free naloxone kits in many community settings.[5] |
| Australia | Not a controlled substance | Available without prescription in pharmacies. Government-subsidized through harm reduction programs.[5] |
| Italy | OTC | Over-the-counter classification since 1996 — the earliest unrestricted access regime in Europe.[18] |
| France | Some formulations without prescription | Limited non-prescription availability for certain naloxone formulations.[18] |
| EU (general) | Mostly prescription required | Most EU member states require medical prescription. The European Union Drugs Agency (EUDA) recommends expanding access across member states.[18] |
Frequently asked questions
What is Naloxone?
Naloxone is a competitive opioid receptor antagonist of the morphinan class used as the standard treatment for opioid overdose reversal. First synthesized in 1960 and FDA-approved in 1971, it is listed on the WHO Model List of Essential Medicines.
How long does Naloxone last?
Total duration by route of administration — Oral: 1 – 2 hours; Insufflated: 30 – 60 min; Intravenous: 30 – 60 min; Intramuscular: 30 – 60 min. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Naloxone?
Psychedex publishes a dosage table for Naloxone on this page covering these routes of administration: intravenous, intramuscular, insufflated, oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Naloxone?
The highest-severity documented interactions for Naloxone: Anticholinergics (Dangerous), Antipsychotics (Dangerous), Benzodiazepines, Barbiturates (Dangerous), GHB, GBL (Dangerous), Ibogaine (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Naloxone addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Naloxone: tolerance builds none. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abKhan S, Tyson AS, Ranjbar M, et al. (2025) Structural snapshots capture nucleotide release at the mu-opioid receptor — Nature doi:10.1038/s41586-025-09677-6
- [2]
- [3] ^abcdKolbe L, Fins JJ (2021) The Birth of Naloxone: An Intellectual History of an Ambivalent Opioid — Cambridge Quarterly of Healthcare Ethics doi:10.1017/s0963180121000116
- [4]
- [5]
- [6]
references
- [1] ^abcKhan S, Tyson AS, Ranjbar M, et al. (2025) Structural snapshots capture nucleotide release at the mu-opioid receptor — Nature doi:10.1038/s41586-025-09677-6
- [2]
- [3] ^abcdKolbe L, Fins JJ (2021) The Birth of Naloxone: An Intellectual History of an Ambivalent Opioid — Cambridge Quarterly of Healthcare Ethics doi:10.1017/s0963180121000116
- [4]
- [5]
- [6]